MASTERINVEST Kapitalanlage GmbH purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 56,941 shares of the biopharmaceutical company's stock, valued at approximately $1,371,000.
Other large investors also recently bought and sold shares of the company. Evolution Wealth Management Inc. grew its holdings in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $26,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC grew its stake in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 650 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Stock Performance
Shares of NYSE PFE opened at $28.00 on Friday. The firm's 50-day moving average price is $25.49 and its 200-day moving average price is $26.29. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a market cap of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer's payout ratio is currently 226.32%.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on PFE. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and reduced their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Weiss Ratings cut Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Finally, Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $28.28.
Read Our Latest Stock Report on PFE
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
- Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season
Pfizer Profile
(
Free Report)
Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
